Chardan Capital reiterated their buy rating on shares of Agenus (NASDAQ:AGEN – Free Report) in a research note released on Monday morning,Benzinga reports. Chardan Capital currently has a $40.00 target price on the biotechnology company’s stock. A number of other equities analysts have also recently commented on AGEN. B. Riley Financial reaffirmed a “buy” rating […]